drugset / Trial / NCT02412917

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

NCT02412917

Phase 3 Terminated 237 enrolled ContraVir Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).

Timeline

Start
2015-06
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject VALNIVUDINE Small molecule 400 mg
Comparator Valacyclovir Unknown 1000 mg